Your browser doesn't support javascript.
loading
Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
Chanut, Mathilde; Jaidi, Rym; Kohn, Milena; Grange, Thomas; Brones, Clara; Lombion, Naëlle; Rousselot, Philippe; Longval, Thomas.
Afiliação
  • Chanut M; Centre Hospitalier de Versailles, Hematologie Oncologie, Le Chesnay, France.
  • Jaidi R; Centre Hospitalier de Versailles, Hematologie Oncologie, Le Chesnay, France.
  • Kohn M; Centre Hospitalier de Versailles, Hematologie Oncologie, Le Chesnay, France.
  • Grange T; Centre Hospitalier de Versailles, Hematologie Oncologie, Le Chesnay, France.
  • Brones C; Centre Hospitalier de Versailles, Hematologie Oncologie, Le Chesnay, France.
  • Lombion N; Centre Hospitalier de Versailles, Hematologie Oncologie, Le Chesnay, France.
  • Rousselot P; Centre Hospitalier de Versailles, Hematologie Oncologie, Le Chesnay, France.
  • Longval T; Centre Hospitalier de Versailles, Hematologie Oncologie, Le Chesnay, France.
Platelets ; 33(4): 652-653, 2022 May 19.
Article em En | MEDLINE | ID: mdl-35225144
ABSTRACT
In 2021, the world experienced the most extensive vaccination campaign to defeat COVID-19. Many cases of idiopathic thrombocytopenia have been reported following injections of SARS-Cov-2 mRNA vaccine. We present the case of a 73-year-old woman with de novo ITP after a first injection of SARS-Cov-2 mRNA vaccine (Moderna vaccine) who experienced a successful rechallenge of SARS-Cov-2 mRNA vaccine (Pfizer vaccine) a few months later.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / Púrpura Trombocitopênica Idiopática / COVID-19 Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Aged / Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / Púrpura Trombocitopênica Idiopática / COVID-19 Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Aged / Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article